| A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors (NCT07703878) | Gilead Sciences | 2026-07-17 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens (NCT07683000) | Gilead Sciences | 2026-07-14 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy (NCT07682961) | Gilead Sciences | 2026-07-14 |
| Study of GS-0415 and How It Works in People With HIV (NCT07719491) | Gilead Sciences | 2026-07-01 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (NCT07546812) | Gilead Sciences | 2026-07-01 |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 (NCT07645287) | Gilead Sciences | 2026-06-15 |
| Study of GS-2426 in Participants With Advanced Solid Tumors (NCT07601243) | Gilead Sciences | 2026-06-02 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer (NCT07527858) | Gilead Sciences | 2026-05-19 |
| Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention (NCT07473778) | Gilead Sciences | 2026-03-17 |
| Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease (NCT06682234) | Gilead Sciences | 2025-12-01 |
| Study of GS-5319 in Adults With Solid Tumors (NCT07128303) | Gilead Sciences | 2025-08-28 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV (NCT07055451) | Gilead Sciences | 2025-08-12 |
| Study of GS-1219 in Participants With HIV-1 (NCT07115368) | Gilead Sciences | 2025-08-11 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus (NCT07096193) | Gilead Sciences | 2025-07-31 |
| Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) (NCT07047716) | Gilead Sciences | 2025-07-22 |
| Study of GS-3242 in Participants With HIV-1; Substudy-05 (NCT07001319) | Gilead Sciences | 2025-05-29 |
| Study of GS-0151 in Participants With Rheumatoid Arthritis (NCT06902519) | Gilead Sciences | 2025-05-14 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (NCT06801834) | Gilead Sciences | 2025-04-04 |
| Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children (NCT06749054) | Gilead Sciences | 2025-03-26 |
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection (NCT06784973) | Gilead Sciences | 2025-03-05 |
| A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain (NCT06683482) | Gilead Sciences | 2025-02-21 |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 (NCT06727565) | Gilead Sciences | 2025-02-18 |
| Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 (NCT06532656) | Gilead Sciences | 2024-11-20 |
| Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated (NCT06613685) | Gilead Sciences | 2024-10-21 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (NCT06585150) | Gilead Sciences | 2024-10-14 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (NCT06630286) | Gilead Sciences | 2024-10-09 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (NCT06630299) | Gilead Sciences | 2024-10-08 |
| Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) (NCT06513312) | Gilead Sciences | 2024-10-07 |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (NCT06486441) | Gilead Sciences | 2024-08-28 |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (NCT06562907) | Gilead Sciences | 2024-08-28 |
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (NCT06337032) | Gilead Sciences | 2024-08-27 |
| Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (NCT06544733) | Gilead Sciences | 2024-08-20 |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors (NCT06532565) | Gilead Sciences | 2024-07-26 |
| Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (NCT06290934) | Gilead Sciences | 2024-03-27 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (NCT06333808) | Gilead Sciences | 2024-03-25 |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors (NCT06167317) | Gilead Sciences | 2024-01-09 |
| Study of Obeldesivir in Children and Adolescents With COVID-19 (NCT05996744) | Gilead Sciences | 2023-12-26 |
| Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) (NCT06104306) | Gilead Sciences | 2023-12-13 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) (NCT06101342) | Gilead Sciences | 2023-12-13 |
| Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (NCT06029972) | Gilead Sciences | 2023-12-05 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) (NCT06101329) | Gilead Sciences | 2023-11-17 |
| Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors (NCT06082960) | Gilead Sciences | 2023-10-09 |
| Study of GS-0272 in Participants With Rheumatoid Arthritis (NCT06031415) | Gilead Sciences | 2023-09-28 |
| Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) (NCT06060665) | Gilead Sciences | 2023-09-05 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection (NCT05729568) | Gilead Sciences | 2023-05-15 |
| Study of GS-4528 in Adults With Solid Tumors (NCT05840224) | Gilead Sciences | 2023-05-11 |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (NCT05840211) | Gilead Sciences | 2023-05-08 |
| Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) (NCT05629208) | Gilead Sciences | 2023-04-17 |
| Study of Novel Treatment Combinations in Patients With Lung Cancer (NCT05633667) | Gilead Sciences | 2023-03-16 |
| Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function (NCT05765344) | Gilead Sciences | 2023-03-15 |
| A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function (NCT05760300) | Gilead Sciences | 2023-03-15 |
| Study of Obeldesivir in Nonhospitalized Participants With COVID-19 (NCT05715528) | Gilead Sciences | 2023-02-08 |
| Study of Bulevirtide in Participants With Chronic Hepatitis D Infection (NCT05718700) | Gilead Sciences | 2023-02-07 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) (NCT05633654) | Gilead Sciences | 2022-12-12 |
| Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness (NCT05603143) | Gilead Sciences | 2022-11-05 |
| Study of Novel Antiretrovirals in Participants With HIV-1 (NCT05585307) | Gilead Sciences | 2022-10-26 |
| Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NCT05502237) | Gilead Sciences | 2022-10-12 |
| Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels (NCT05458102) | Gilead Sciences | 2022-08-19 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (NCT05502341) | Gilead Sciences | 2022-08-16 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (NCT05382286) | Gilead Sciences | 2022-07-25 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (NCT05382299) | Gilead Sciences | 2022-07-20 |
| Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (NCT05330429) | Gilead Sciences | 2022-07-08 |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (NCT05079230) | Gilead Sciences | 2022-07-07 |
| Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment (NCT05165771) | Gilead Sciences | 2022-07-01 |
| Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women (NCT05281510) | Gilead Sciences | 2022-06-09 |
| Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NCT05186974) | Gilead Sciences | 2022-05-30 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT04958785) | Gilead Sciences | 2021-12-14 |
| Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT05089734) | Gilead Sciences | 2021-11-17 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma (NCT04892446) | Gilead Sciences | 2021-11-09 |
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (NCT05101096) | Gilead Sciences | 2021-10-20 |
| Study of Sacituzumab Govitecan in Patients With Solid Tumor (NCT05119907) | Gilead Sciences | 2021-10-12 |
| Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV (NCT05052996) | Gilead Sciences | 2021-10-05 |
| Study of Magrolimab in Patients With Solid Tumors (NCT04827576) | Gilead Sciences | 2021-10-01 |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (NCT04854499) | Gilead Sciences | 2021-09-07 |
| Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) (NCT04809623) | Gilead Sciences | 2021-09-01 |
| Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (NCT04994509) | Gilead Sciences | 2021-08-30 |
| Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) (NCT04891770) | Gilead Sciences | 2021-08-14 |
| Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (NCT04971785) | Gilead Sciences | 2021-08-09 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria (NCT04827589) | Gilead Sciences | 2021-07-01 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (NCT04778397) | Gilead Sciences | 2021-07-01 |
| Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (NCT04925752) | Gilead Sciences | 2021-06-28 |
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies (NCT04778410) | Gilead Sciences | 2021-06-28 |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment (NCT04617522) | Gilead Sciences | 2021-04-06 |
| Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) (NCT04745351) | Gilead Sciences | 2021-03-31 |
| Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors (NCT04747470) | Gilead Sciences | 2021-03-25 |
| Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (NCT04527991) | Gilead Sciences | 2021-01-13 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy (NCT04483700) | Gilead Sciences | 2020-12-01 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy (NCT04483687) | Gilead Sciences | 2020-12-01 |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (NCT04639986) | Gilead Sciences | 2020-11-23 |
| Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04502706) | Gilead Sciences | 2020-11-17 |
| Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants (NCT04608344) | Gilead Sciences | 2020-11-04 |
| Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments (NCT04454437) | Gilead Sciences | 2020-10-23 |
| Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting (NCT04501952) | Gilead Sciences | 2020-09-18 |
| Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation (NCT04539262) | Gilead Sciences | 2020-09-14 |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (NCT04313881) | Gilead Sciences | 2020-09-09 |
| Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy (NCT04319198) | Gilead Sciences | 2020-08-04 |
| Study of Remdesivir in Participants Below 18 Years Old With COVID-19 (NCT04431453) | Gilead Sciences | 2020-07-21 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment (NCT04292730) | Gilead Sciences | 2020-03-15 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) (NCT04292899) | Gilead Sciences | 2020-03-06 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (NCT04211909) | Gilead Sciences | 2020-01-03 |